ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferon"

  • Abstract Number: 2397 • ACR Convergence 2024

    Increase of IL10 and IFNa2 Are Associated to Clinical Activity in Systemic Lupus Erythematous Patients

    Elena Grau García1, Marta De la Rubia Navarro2, Samuel Leal Rodriguez1, José Ivorra-Cortés3, Carmen Riesco Barcena4, Anderson Huaylla Quispe4, Laura Mas Sánchez5, Pablo Muñoz Martínez6, Daniel Ramos Castro4, Alba Torrat noves7, Iago Alcantara Alvarez2, Belén Villanueva Mañés2, Miguel Simeo Vinaixa2, Andrés Pérez Hurtado4 and Jose A Román-Ivorra8, 1HUP La Fe, Valencia, Spain, 2Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 3Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, 4Rheumatology Department. HUP La Fe, Valencia, Spain, 5Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, 6Hospital Universitario y Politècnico La Fe, Sagunto, Spain, 7Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, 8Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain

    Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by deregulation of cytokine production. Interferon (IFN) is a proinflamatory cytokine considered as a key…
  • Abstract Number: 0970 • ACR Convergence 2024

    Deubiquitylase (DUB) BRCC36 Isopeptidase Complex (BRISC) Inhibitors Prevent IFNAR1 Deubiquitination to Restore Natural Type I IFN Response in Autoimmunity

    Rebecca Ross1, Poli Adi Narayanna Reddy2, Joseph Salvino2, Elton Zeqiraj3 and Francesco Del Galdo3, 1Medicine and Health, University of Leeds, Leeds, United Kingdom, 2The Wistar Institute, Philadelphia, PA, 3University of Leeds, Leeds, United Kingdom

    Background/Purpose: Increased Type I IFN activation plays a key role in Scleroderma (SSc), Systemic Lupus Erythematosus and Inflammatory Myositis. Deubiquitylase (DUB) BRCC36 isopeptidase complex (BRISC)…
  • Abstract Number: 1770 • ACR Convergence 2024

    Assessing S100A4 and Myofibroblast Phenotypes in the Pathogenesis of Cardiac and Cutaneous Neonatal Lupus

    Nalani Sachan1, Christina Firl2, Philip Carlucci3, Nicola Fraser2, Robert Clancy4 and Jill Buyon5, 1NYU Grossman School of Medicine, New York, NY, 2NYU Langone Health, New York, NY, 3New York University School of Medicine, New York, NY, 4Columbia University Medical Center, New York, NY, 5New York University Grossman School of Medicine, New York, NY

    Background/Purpose: Neonatal lupus (NL), driven by fetal exposure to maternal anti-SSA/Ro autoantibodies, typically results in permanent cardiac manifestations in utero and/or a transient rash postnatally.…
  • Abstract Number: 2423 • ACR Convergence 2024

    Associations Between Cytometric Interferon Signature and Clinical Response in a Cohort of Anifrolumab-treated Patients with Lupus

    Alice Horisberger1, Katharina Shaw2, Eilish Dillon3, Kathryne Marks4, Rochelle Castillo5, Ifeoluwakiisi Adejorin6, Kimberly Hashemi4, Karen Costenbader7, Avery LaChance8, Ruth Ann Vleugels5 and Deepak Rao1, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Perelman School of Medicine at the University of Pennsylvania, Merion Station, PA, 3University of Massachusetts Boston, Yarmouth, MA, 4Brigham and Women's Hospital, Boston, MA, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, 8Brigham and Women's Hospital, Jamaica Plain, MA

    Background/Purpose: Anifrolumab, a monoclonal antibody targeting type I interferon (IFN-I) receptor subunit 1, was recently approved for the treatment of systemic lupus erythematosus (SLE) and…
  • Abstract Number: 0001 • ACR Convergence 2024

    Type I Interferon and Anifrolumab Effects on Bone Marrow and Blood Plasma Cells in Systemic Lupus Erythematosus

    Diana Alzamareh1, Nida Pellett2, Daria Krenitsky2, Wesley Durrett1, Javier Rangel-Moreno1, Jennifer Anolik2 and Jennifer Barnas1, 1University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of pathogenic anti-nuclear antibodies (ANA) by plasma cells (PC).  Importantly, long-lived plasma…
  • Abstract Number: 1150 • ACR Convergence 2024

    Increased ISG15 Expression in Peripheral Blood from Patients with Positive Dermatomyositis Related Specific Autoantibodies

    Sylvia Raftopoulou1, Nikolaos Michalakeas1, Maria Gerochristou2, Nikolaos Marketos1, Charalampos Skarlis1 and Clio Mavragani3, 1Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, 2Andreas Syggros Hospital, National and Kapodistrian University of Athens, Athens, Greece, 3Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterised by muscle inflammation (myositis) and weakness, impacting various organ systems. Clinical subtypes include dermatomyositis (DM), antisynthetase syndrome (ASyS),…
  • Abstract Number: 1772 • ACR Convergence 2024

    Modeling and Predicting HLH Through Measurement of Immune Synapse Duration, Cytokine Production, and Target Cell Death

    Anastasia Frank-Kamenetskii1, Jemy Varghese2, Jeremy Morrissette3, Hannah Klinghoffer4, Caroline Diorio5, Janis Burkhardt6 and Scott Canna2, 1CHOP/UPENN, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA, 4The Children's Hospital of Philadelphia, Philadelphia, PA, 5Division of Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 6The Children's Hospital of Philadelphia, Philadelphia

    Background/Purpose: Hyperinflammation is a life-threatening systemic inflammatory state most commonly associated with Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS), but observed in nearly all inflammatory…
  • Abstract Number: 2456 • ACR Convergence 2024

    High Levels of Circulating IFNα Are Associated with Increased Mortality in Patients with Diffuse Cutaneous Systemic Sclerosis

    François Maillet1, Carine Schmidt1, Vincent Bondet2, Alexandre Bense1, Darragh Duffy3, Luc Mouthon1, Mathieu Paul Rodero4 and Benjamin Chaigne5, 1AP HP, Paris, France, 2INSERM PAsteur Institute, Paris, France, 3Inserm Pasteur Institue, Paris, France, 4Université Paris CIté, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Faculté des Saint-Pères, Paris, France, 5Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France

    Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by skin and organ fibrosis, autoimmunity, and vasculopathy. Although its pathophysiology remains unclear, recent data…
  • Abstract Number: 0020 • ACR Convergence 2024

    CD14 Deficiency Protects Against TLR4/LPS-mediated Inhibition of Osteoclastogenesis

    Lance Murphy1, Kevin Burt2, Vu Nguyen3, Baofeng Hu2, Robert Mauck3 and Carla Scanzello2, 1University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Philadelphia

    Background/Purpose: Osteoarthritis is associated with bone changes such as subchondral sclerosis, bone marrow lesions, and osteophyte formation (Donel S, 2019). Prior work has demonstrated that…
  • Abstract Number: 1266 • ACR Convergence 2024

    Anti-Mitochondrial Antibodies Associate with Disease Activity and IFNα Expression in Childhood-onset Systemic Lupus Erythematosus

    Marina Barguil Macedo1, Javad Wahadat2, Albin Bjoerk3, Sylvia Kamphuis2, Marjan Versnel2 and Christian Lood1, 1University of Washington, Seattle, WA, 2Erasmus University Medical Center, Rotterdam, Netherlands, 3Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Extracellular mitochondria may represent a source of antigenic burden in autoimmune disorders, such as in systemic lupus erythematosus (SLE), in which those organelles, released…
  • Abstract Number: 1778 • ACR Convergence 2024

    A Novel Variant in IRAK2 Results in Immune Dysregulation in Systemic Juvenile Idiopathic Arthritis (sJIA)

    Mariana Correia Marques1, Brooke Boyd2, Alana Platukus3, Elizabeth Schmitz2, Hiroto Nakano2, Faiza Naz4, Anthony Cruz1, Stefania Dell'Orso4, Zuoming deng4 and Michael Ombrello5, 1National Institutes of Health, Bethesda, MD, 2Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, 31Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD

    Background/Purpose: Lung disease (LD) is poorly understood complication of Still’s disease with high fatality. HLA-DRB1*15 is a strong risk factor for the development of this…
  • Abstract Number: 2518 • ACR Convergence 2024

    Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype

    Yesim Ozguler1, Olivier Manches2, Didar Ucar3, Ziyan Lin2, Alireza Khodadadi-Jamayran2, Aristotelis Tsirigos2, Gulen Hatemi1 and Johannes Nowatzky4, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2NYU Grossman School of Medicine, New York, NY, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 4New York University Grossman School of Medicine, New York, NY

    Background/Purpose: The immune landscape of Behçet’s disease (BD) remains ill-defined, lacking a unifying picture, precise disease phenotype-endotype correlations, and an understanding of immunity at target…
  • Abstract Number: 0092 • ACR Convergence 2024

    A New Generation Mesenchymal Stromal Cell (MSC)-based Cell Therapy Using Design of Experiments Halts Pristane Induced Glomerulosclerosis

    Hulya Bukulmez1, Adrienne Dennis2, kristine Highland3 and Steven N. Emancipator4, 1MetroHealth Medical Center, Case Western Reserve, Pepper Pike, OH, 2MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, 3Cleveland Clinic Foundation, Cleveland, OH, 4Case Western Reserve University, Cleveland, OH

    Background/Purpose: MSCs, exposed to a disease-specific cytokine profile, can accurately sense the composition of the inflammatory microenvironment. We have harnessed this adaptive ability of MSCs…
  • Abstract Number: 1426 • ACR Convergence 2024

    Single Cell RNA-Seq Characterization of Circulating Immune Cells in Sjogren’s Syndrome: Comparison to SLE and Rheumatoid Arhtritis

    Alejandro Gomez-Gomez1, yolanda Guillen2, Paloma Vela Casasempere3, María Paula álvarez Hernández4, Ignacio Brana Abascal5, Mónica Fernández Castro6, Maria López Lasanta1, José María Pego-Reigosa7, Carlos Marras8, María García-Villanueva9, Francisco Blanco10, Patricia Carreira11, Carolina Perez-Garcia12, Íñigo Rúa-Figueroa13, Hugo F Avalos bogado1, Natalia Boix Martí1, Eric Kirkegaard-Biosca14, iago álvarez Sáez15, Nuria Palau16, Raül Tortosa16, Jesús Tornero Molina17, Antonio Fernandez Nebro18, Jaime Calvo-Alén19, Juan Cañete20, Damiana Alvarez-Errico2, Ernest Choy21, Holger Heyn22, Antonio Julia23, Sara Marsal barril1 and Jose Luis Andreu24, and on behalf of SSAD and DocTIS consortia, 1Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, 2Imidomics, Inc, Barcelona, Spain, 3Hospital General Universitario de Alicante , Rheumatology, Alicante, Spain, 4Hospital universitario de la Princesa. IIS-Princesa, Rheumatology, Madrid, Madrid, Spain, 5Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, 6Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain, 7Galicia Health Service (SERGAS), Vigo, Spain, 8Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, 9Hospital Ramón y Cajal, MADRID, Madrid, Spain, 10Complejo Hospitalario Universitario de A Coruña , Rheumatology, A Coruña, Spain, 11Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, 12Hospital del Mar, Barcelona, Spain, 13Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, 14Hospital Universitari Vall d´Hebron, Ophtalmology, Barcelona, Spain, 15Hospital Universitari Vall d´Hebron, Maxillofacial Surgery, Barcelona, Spain, 16Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, 17Sociedad Española de Reumatologia, Rheumatology, Madrid, Spain, 18Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, 19Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, 20Hospital Clinic an IDIBAPS, Barcelona, Spain, 21Cardiff University School of Medicine, Cardiff, United Kingdom, 22Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, 23Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 24Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain

    Background/Purpose: Primary Sjögren’s Syndrome (pSS) shares with SLE and RA features including their predominance in women, immunological characteristics and genetic risk background. Hence, to dissect…
  • Abstract Number: 1792 • ACR Convergence 2024

    CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus

    Lauren Robinson1, Preetha Balasubramanian2, Zurong Wan2, Juan Rodriguez Alcazar2, Marina Lima Silva Santos2, Lynnette Walters3, Jeanine Baisch2, Karen Onel4, Tracey Wright5, Virginia Pascual6 and Simone Caielli2, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Scottish Rite Hospital for Children, Allen, TX, 4HSS, New York, NY, 5UT Southwestern, Plano, TX, 6Weill Cornell Medical College, New York, NY

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology